Natera Inc · Q2 2020 earnings

Briefing

Reported strong volume and revenue despite COVID-19 impact, achieving major milestones across oncology and transplant businesses.

Natera reported total revenues of $86.5 million for the second quarter of 2020, compared to $74.4 million for the second quarter of 2019. The increase was primarily driven by sales of Panorama and Horizon tests. The company processed 234,100 tests in the second quarter of 2020, including approximately 221,600 tests accessioned in its laboratory.

• Total revenues were $86.5 million in the second quarter of 2020, compared to $74.4 million for the second quarter of 2019.
• Natera processed 234,100 tests in the second quarter of 2020, including approximately 221,600 tests accessioned in its laboratory.
• Loss from operations for the second quarter of 2020 was $51.6 million compared to $28.6 million for the same period of the prior year.
• Net loss for the second quarter of 2020 was $59.6 million, or ($0.75) per diluted share, compared to net loss of $32.4 million, or ($0.48) per diluted share, for the same period in 2019.

Headline financials

Revenue & EPS history

Natera anticipates 2020 total revenue of $345 million to $365 million; 2020 cost of revenues to be approximately 51% to 55% of revenues; selling, general and administrative costs to be approximately $260 million to $280 million; research and development costs to be $85 million to $95 million, and net cash burn to be $125 million to $155 million.